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SUMMARY
Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is associated with 40%
mortality at 40 months.
To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled,
16-week studies were initiated. Safety concerns are particularly relevant in SCD due to comorbid
conditions. ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and
pulmonary venous hypertension (PH), respectively. Hemodynamics and 6-minute walk distance
(6MWD) were obtained at baseline and week 16.
The studies were terminated due to slow site initiation and patient enrolment (n=26). Bosentan
appeared to be well tolerated. Although sample sizes were limited, in ASSET-1 at baseline,
6MWD correlated with cardiac output (CO; p=0.006) with non-significant correlations between
6MWD and pulmonary vascular resistance (PVR; p=0.07) and between 6MWD and right atrial
pressure (p=0.06). In ASSET-2 at baseline, there was a non-significant correlation between
6MWD and CO (p=0.06). Due to limited sample sizes, efficacy endpoints were not analyzed.
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However, in both studies, non-significant increases in CO were observed with bosentan compared
to placebo. Similarly, non-significant decreases in PVR were observed with bosentan.
Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan
appears to be well tolerated. Further investigation is warranted.
Keywords
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INTRODUCTION
Three adult screening studies in sickle cell disease (SCD) have reported a 20% prevalence of
mild pulmonary hypertension (PH), defined by Doppler-estimated right ventricular systolic
pressure (RVSP) >35 mmHg, and 10% prevalence of at least moderate or greater PH,
defined by RVSP >45 mmHg (Ataga, et al 2006, De Castro, et al 2008, Gladwin, et al
2004). Using Doppler echocardiography, RVSP can be estimated by measuring tricuspid
regurgitant velocity (TRV) with approximation of right atrial pressure (by inspiratory
collapsibility of the vena cava) and subsequent application of the modified Bernoulli
equation. Despite estimated RVSP increases that are much lower than those measured in
patients with idiopathic pulmonary arterial hypertension (IPAH), the mortality rate
associated with mild elevation in estimated RVSP appears to be quite high in adult SCD
patients (Ataga, et al 2006, Castro, et al 2003, De Castro, et al 2008, Gladwin, et al 2004,
Machado, et al 2006), rising linearly with estimated values between 35-45 mmHg associated
with a 4.4-fold mortality (95% confidence interval [CI], 1.6-12.2; p<0.001); an estimated
RVSP >45 mmHg is associated with a 10.6-fold mortality (95% CI, 3.3-33.6; p<0.001)
(Ataga, et al 2006, De Castro, et al 2008, Gladwin, et al 2004). Left-sided heart disease, i.e.
due to left ventricular diastolic dysfunction (LVDD), present in 18% of SCD patients
(assessed by echocardiography), has been reported as an independent risk factor in SCD
(Sachdev, et al 2007). Additionally, in patients with both Doppler-defined PH, i.e. increased
TRV on Doppler echocardiography, and suspected LVDD (by echocardiography), the
mortality risk is compounded (12.0-fold mortality; 95% CI, 3.8 to 38.1; p<0.001) (Sachdev,
et al 2007).
While SCD is most frequent in African populations, it also affects Mediterranean,
Caribbean, South and Central American, Arabian, and East Indian subjects; there are more
than 100,000 SCD patients in the United States alone (Minter and Gladwin 2001). However,
to date only small, uncontrolled studies have investigated potential treatments in SCD-PH
(Castro, et al 2003, Gladwin and Schechter 2001, Little, et al 2009, Machado, et al 2005,
Morris, et al 2003, Sullivan, et al 1999, unpublished observations of Jison et al). Given the
limitations of these studies, well-controlled phase II/III trials are needed to confirm the
safety and efficacy of treatments.
The pathogenesis of SCD-PH appears multi-factorial: vascular occlusion and hemolysis
result in intimal hyperplasia and asplenia promotes pulmonary microthrombosis and
increases cell-free hemoglobin. Additionally, chronic hypoxaemia due to sleep-disordered
breathing, parenchymal and vascular injury resulting from recurrent acute chest syndrome
(ACS), and scavenging of nitric oxide by hemoglobin and arginase released during
hemolysis also appear to contribute to the pulmonary vasculopathy (Ataga, et al 2004,
Gladwin and Vichinsky 2008, Morris, et al 2005, Reiter, et al 2002). Due to high cardiac
output (CO) secondary to chronic anemia, SCD-PH has lower pulmonary vascular resistance
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(PVR) than IPAH (although higher PVR than SCD without PH). Even with mildly increased
pulmonary arterial pressure (PAP) and relatively low PVR, adult SCD patients can have
clinically significant exercise intolerance and functional limitations (Anthi, et al 2007,
Gladwin, et al 2004). Each 10-mmHg increment in mean PAP (PAPm) increases the death
rate by 1.7-fold (Castro, et al 2003).
Due to the reported high prevalence of Doppler-estimated PH in SCD and the high
associated mortality, PH treatments are needed. Because ET-1 appears important in SCD
pathobiology including associated PH, ET-1 receptor antagonism may be efficacious. The
objectives of the ASSET Randomized, Placebo-Controlled, Double-Blind, Multicenter,
Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients
With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell
Disease)-1 and -2 studies were to evaluate the safety and efficacy of bosentan, a dual ET-1
receptor antagonist, in two different subtypes of SCD-PH patients (see Methods). Given that
echocardiography using TRV ≥ 2.5 m/s can overestimate the prevalence of true PH
(confirmed by right heart catheterization (RHC), and because co-existent LVDD appears
prevalent in SCD (Parent, et al 2009, Sachdev, et al 2007), RHC was required for
confirmation of PH for study enrollment. Both ASSET-1 and -2 were stopped prematurely
due to slow site initiation and enrolment.
Despite limited power, the ASSET studies provide the largest multi-center cohort of SCD-
PH patients to date with hemodynamic and exercise data. Due to the limited sample sizes
resulting from premature study discontinuation, safety and efficacy data are presented
descriptively.
METHODS
Patient Population and Study Design
For the purposes of these studies, pulmonary arterial hypertension (PAH) and PH were
defined as follows:
• PAH (precapillary PH) included patients with pulmonary capillary wedge pressure
(PCWP) ≤15 mmHg and PVR ≥160 dyn/sec/cm-5. The 160 dyn/sec/cm-5 PVR
threshold was chosen rather than the traditional 240 dyn/sec/cm-5 in other PAH
subgroups, i.e. IPAH, because even small increases in PVR are associated with
adverse functional outcomes in this population (Anthi, et al 2007, Gladwin, et al
2004).
• PH (“mixed vasculopathy”) included patients with either PCWP ≤15 mmHg and
PVR ≥100 dyn/sec/cm-5 and <160 dyn/sec/cm-5, or PCWP 16 to 25 mmHg and
PVR ≥100 dyn/sec/cm-5.
Two concurrent, randomized, double-blind, placebo-controlled, 16-week studies in SCD
with PAH (ASSET-1) or PH (ASSET-2) were designed.
Enrollment criteria: male or female ≥12 years with PAH enrolled in ASSET-1, or PH
enrolled in ASSET-2. Screening logs were not part of the study. All patients had: SCD
(HbSS or HbS/betao genotype; HbA ≤10%), dyspnea with exertion, 6-minute walk distance
(6MWD) ≥150 m and ≤450 m, clinical stability ≥3 months with no changes in chronic
treatment, i.e. chronic treatment was based on the judgment of the clinical investigator, and
PAH or PH confirmed by RHC at the time of enrollment. Exclusion criteria: left ventricular
ejection fraction <40%, systolic pressure <85 mmHg, uncontrolled hypertension with
systolic pressure >160 mmHg and/or diastolic pressure >100 mmHg, total lung capacity
<50% of predicted, hemoglobin <60 g/l, alanine transaminase (ALT) ≥3× upper limit of
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normal (ULN) or albumin >20% below ULN. Women of childbearing potential had a
negative serum pregnancy test and used reliable methods of contraception during, and for 3
months after study completion.
After obtaining informed consent, all patients underwent RHC. Only those patients with
confirmed PAPm ≥25 mmHg by RHC were assigned to either ASSET-1 or ASSET-2 based
on hemodynamics at randomization. Patients who completed the 16-week study had the
option to enter the open-label study (ASSET-3) without a washout period.
Local institutional review committees approved the protocol; written informed consent was
obtained from all patients.
Eligible patients were randomized 1:1 ratio to either bosentan or placebo (Figure 1). Patients
were started on oral bosentan 62.5 mg b.i.d. or placebo, and up-titrated after 4 weeks to 125
mg b.i.d. or placebo for the remainder of the 16-week study. Safety and efficacy were
assessed at Weeks 4, 8, 12, and 16. Enrollment into the trial was stopped early due to slow
enrollment.
The investigator could discontinue study treatment due to an adverse event (AE), for
administrative reasons (e.g., consent withdrawal), or if continued administration was
considered contrary to the patient’s best interests.
Outcome Measures
The primary endpoint in ASSET-1 was change from baseline in PVR at Week 16. The
primary endpoint in ASSET-2 was change from baseline in 6MWD at Week 16. The 6MWD
was chosen as a functional outcome for ASSET-2 because the PVR was already low, and
less likely to be influenced by a vasodilator. Secondary endpoints included change in
6MWD (ASSET-1), and safety of bosentan in all patients. Additionally, correlations
between hemodynamics and 6MWD were evaluated. The objectives of the open-label
ASSET-3 extension were to collect long-term safety and efficacy data in SCD-PH (PAH and
“mixed vasculopathy”) patients.
Statistical Analyses
Hemodynamics and 6MWD correlations were analyzed by Spearman’s rank. Correlation
analyses were performed on the treatment-per-protocol populations of ASSET-1 and -2 to
determine the potential influence of hemodynamics on 6MWD at baseline. Multivariate
regression models were performed to examine hemodynamic predictors of 6MWD at
baseline. Pre- and post-treatment parameters were analyzed in both treatment groups in each
study by comparing median differences between bosentan and placebo groups. In case of
missing values, the last available post-baseline value was carried forward unless a
substitution rule applied. For death, the 6MWD was 0 m. Patients without RHC at week 16
were not included in paired analyses. Due to the exploratory nature of the analyses, no
correction for multiple comparisons was applied. P<0.05 was considered statistically
significant. Actelion Pharmaceuticals, Ltd. sponsored the study. Statistical analyses were
performed independently by the authors.
RESULTS
Patients
Twenty-six patients were randomized (14 in ASSET-1; 12 in ASSET-2) before enrollment
was stopped due to slow site initiation and enrollment. Enrolled patients remained on study
medication, i.e. placebo or bosentan, until their study participation was completed. Baseline
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demographics of the patients enrolled in the controlled studies were similar to other PAH
studies with the exception of race (Table 1). All patients were African-American.
Demographics of the two treatment groups were similar, with the exception of body weight
(median weight bosentan 83.5 kg vs. placebo 68.9 kg; data not shown).
The disposition of all patients is shown in Figure 2. Treatment remained blinded for all
patients until database lock. Eleven patients continued in the open-label (ASSET-3).
Two patients in each treatment group had blinded drug discontinued prematurely. The two
patients on bosentan were discontinued from ASSET-1 due to an AE; one who had
developed sepsis, subsequently died from it. The two patients on placebo were discontinued
from ASSET-1 due to investigator withdrawal and patient consent withdrawal. None of the
11 patients who continued in ASSET-3 discontinued prematurely. One death occurred in the
controlled studies as mentioned above, and none in the open-label ASSET-3. The patient
who died in the controlled study was hospitalized for vaso-occlusive crisis (VOC), at which
time study drug (bosentan) was discontinued. While in the hospital, the patient developed
sepsis and died 15 days after study treatment discontinuation. The investigator considered
the VOC and sepsis unrelated to study treatment. In ASSET-3 (open label extension), the
median drug exposure was 24.6 weeks (range 11.0 – 35.6 weeks).
Hemodynamic Parameters
Baseline hemodynamics (Table 1) were consistent with prior studies, i.e. SCD-PAH patients
exhibited a moderate PAPm elevation and high CO, with associated modest PVR elevation
and decreased 6MWD. The 6MWD was also decreased in the SCD-PH patients with modest
increases in PCWP.
Correlations with 6MWD and Hemodynamics at Baseline
Despite the small sample sizes, in ASSET-1, a significant correlation between CO and
6MWD was observed (p=0.006), with potential inverse correlations (not significant) for
RAPm and 6MWD (p=0.06), and for PVR and 6MWD (p=0.07; Table 2; Figure 3). In
ASSET-2, a potential correlation between CO and 6MWD (p=0.06) and a potential inverse
correlation between PCWP and 6MWD (p=0.08) were observed (Table 2; Figure 4).
Multivariate regression modeling examining the hemodynamic predictors of 6MWD at
baseline demonstrated that 55% of the total variation in 6MWD was explained by the
hemodynamic parameters (Table 3A). Table 3B shows that CO remained significant
(p=0.0002) in the generated predictive model. No correlations were observed between
haemoglobin and 6MWD, or between haemoglobin and CO.
Treatment Effect on 6MWD and Hemodynamics
While not analyzed for efficacy, the changes in 6MWD and in hemodynamics from baseline
to Week 16 are summarized in Table 4. One patient withdrew consent before a post-baseline
assessment was obtained and was excluded from this analysis.
While not significant, in both studies greater increases in median 6MWD were observed in
the placebo vs. bosentan groups at study end compared with baseline (Table 4; Figure 5);
additionally, there was a non-significant increase in median CO in the bosentan groups and a
non-significant decrease in the placebo groups (Table 3). A greater PVR reduction (not
significant) also occurred in the bosentan vs. placebo groups in both studies (Figure 6; Table
3).
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Serious adverse events (SAEs) occurred in a similar proportion of patients in each treatment
group, and except for VOCs, each event occurred in a single patient per treatment group
(Tables 5-6). During the open-label, three of the 11 patients experienced an SAE, which
included a VOC in each case.
Bosentan appeared to be well tolerated. In the double-blind studies, AEs were reported for
most patients in both treatment groups. No apparent differences between treatments in the
number or types of AEs were observed nor evidence of a relationship to treatment in the
number or type of events that were graded as severe or serious. Clinically significant
decreases in hemoglobin (pre-specified as >15% decrease in hemoglobin to an absolute
value <110 g/l) occurred in four patients in each treatment group, with no consequent patient
dropout. No increases in liver function tests (ALT >3× ULN) were observed. Asymptomatic
decreases in mean systolic (−9.3 vs. −7.3 mmHg on placebo) and diastolic pressures (−7.9
vs. −0.9 mmHg on placebo) and mean increase in body weight (0.8 vs. −0.3 kg on placebo)
were observed with bosentan. These differences were neither clinically nor statistically
significant. Differences between treatments in laboratory variables, heart rate, or
electrocardiography were also not clinically or statistically significant.
In the open-label, no deaths, discontinuations due to an AE, elevations in ALT >3× ULN, or
symptoms of liver disease occurred. Three patients experienced an SAE, which included a
VOC in each case.
DISCUSSION
The neurohormone ET-1 causes vasoconstriction and promotes fibrosis, cell proliferation,
remodeling, and inflammation. In PAH and heart failure, ET-1 concentrations correlate with
disease severity and prognosis. Although no data are available in SCD correlating ET-1
levels with PH, elevated ET-1 levels in SCD (Hammerman, et al 1997, Rybicki and
Benjamin 1998, Werdehoff, et al 1998) support a pathobiological role of ET-1 in SCD-PH.
ET-1 levels rise with VOCs and decline with resolution (Graido-Gonzalez, et al 1998).
Sickled erythrocytes induce ET-1 expression (Phelan, et al 1995). ET-1 modulates Gardos
channel activity in erythrocytes (Rivera, et al 2002), triggering further erythrocyte sickling.
As the ET-1 elevations precede clinical symptoms (Hammerman, et al 1997), ET-1 blockade
could also prevent VOCs and ameliorate the disease.
Based on these studies, the ASSET trials were designed to evaluate the safety and efficacy
of bosentan, a dual ET-1 receptor antagonist, in SCD-PH. However, due to slow site
initiation and enrollment, the studies were stopped prematurely. As no screening logs were
kept at the recruiting sites, we were unable to analyze screen failure data. Given the small
sample sizes, efficacy endpoints were also not analyzed. Echocardiograms on these patients
were not performed simultaneously with RHCs, so we were unable to analyze sensitivity
and specificity of echocardiographic indices compared to cardiac catheterization parameters.
However, despite the small sample sizes, correlations between hemodynamics and 6MWD
were observed in SCD-PH patients, as suggested by a previous study (Anthi, et al 2007). In
particular, a potential correlation between 6MWD and CO was observed. These findings
were significant in PAH patients in ASSET-1 (consistent with other studies in World Heath
Organization Group I PAH), while associations were not significant in PH patients in
ASSET-2. Interestingly, a trend towards an increase in CO was noted with bosentan, but this
was not borne out by the 6MWD data. Given that the standard error for CO is much smaller
than that for 6MWD, and that the 6MWD can be affected by comorbid conditions, these
results are not surprising. Similar results have been noted in smaller Phase II studies of other
agents for PAH (Barst, et al 2002, Rubin, et al 1990).
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Anemia, by decreasing oxygen carrying capacity, reduces systemic oxygen transport.
However, in SCD, there is a compensatory increase in CO to maintain tissue perfusion. And
although CO is higher in SCD-PH than in non-anemic PH patients (without SCD), it remains
lower than in SCD without PH (Anthi, et al 2007). Thus, the observed increase in CO with
bosentan in SCD-PH should improve systemic oxygen transport thereby minimizing the
adverse cardiovascular effects observed in SCD-PH.
Although bosentan has been approved for other PAH patients, SCD has additional comorbid
events (e.g. VOCs, anemia). Safety endpoints in the placebo-controlled studies (using an
integrated database of all 26 patients) and the open-label were analyzed, and were consistent
with bosentan being well tolerated with no unexpected safety concerns.
The walk-PHaSST trial (double-blind, randomized controlled trial with sildenafil in SCD-
PH [Doppler-defined] patients) was recently prematurely terminated due to safety concerns,
i.e. increased VOCs in the sildenafil vs. placebo patients (NHLBI Office of
Communications, 2009). In contrast, there were no increased episodes of VOCs, other AEs
or SAEs in the bosentan patients in ASSET -1 or -2. Although sildenafil is approved for
PAH (confirmed by RHC), the early termination of walk-PHaSST highlights the importance
of performing well-designed trials to assess safety and efficacy in each specific patient
subpopulation. However, it is also important to appreciate that the walk-PHaSST population
was not identical to ASSET. Walk-PHaSST included all SCD patients with TRV ≥2.7m/s
with only TRV ≥3.0 m/s patients having a RHC at baseline. In contrast, all ASSET patients
had PH confirmed by RHC at enrollment.
Minniti et al (2009) recently reported improved exercise capacity in 14 SCD-PH patients
after 6 months of treatment with either the dual ET-1 receptor antagonist bosentan or the
endothelin type-A selective receptor antagonist ambrisentan. Although these observations
were limited by an absence of a placebo arm and all patients were from a single center, these
data are consistent with the ASSET data.
Potential safety issues associated with bosentan, i.e. decreased hemoglobin and
hepatotoxicity, are relevant in SCD. Although the decrease in hemoglobin was greater with
bosentan versus placebo, no patient had study treatment discontinued due to worsening
anemia. These findings are similar to observations in much larger populations of patients
without SCD. Because SCD patients have elevated levels of aspartate transaminase (AST),
indirect bilirubin, and lactate dehydrogenase due to chronic hemolysis, regular monitoring
for liver injury relied on ALT and direct bilirubin and not on AST levels. Throughout the
studies, no patients had ALT >3× ULN or required a dose change or discontinuation of
study drug due to hepatotoxicity.
Recent data suggest that using TRV ≥2.5 m/s to define PH may lead to a false-positive rate
as high as 77%, with PH defined as PAPm ≥25 mmHg (Parent, et al 2009). However, it is
possible that the increased TRV was observed because echocardiography was performed
during a VOC or an ACS episode. As RHCs are usually performed after crisis resolution,
this may contribute to a high false-positive rate. Furthermore, whether the increased
mortality rate is confined to the subset with hemodynamically confirmed PH (by right heart
catheterization), rather than the overall SCD group with TRV ≥2.5 m/s remains unclear. All
patients enrolled in ASSET had PH confirmed by RHC before randomization. However,
even patients with a TRV ≥2.5 m/s who do not have confirmed PH may have isolated
pulmonary systolic hypertension that may be associated with an increased mortality rate,
particularly in association with an additional “trigger”, such as a VOC, known to acutely
increase pulmonary pressures in SCD (Gladwin and Vichinsky 2008, Machado, et al 2007,
Mekontso Dessap, et al 2008).
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In conclusion, these limited data suggest that 16 weeks of bosentan in SCD patients with
confirmed PH (by right heart catheterization) was well tolerated and continued to be well
tolerated in the open-label study. Despite small sample sizes, the correlations between
exercise capacity and hemodynamics were consistent with previous reports in other PAH
patients, supporting the hypothesis that even mild PH may be clinically significant in SCD.
With premature discontinuation of the studies, efficacy analyses were not performed due to
the limited sample sizes. With the only other oral class of approved PAH therapies, i.e.
phosphodiesterase-5 inhibitors, not appearing to be well tolerated in SCD patients, further
investigation appears to be warranted.
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Fig 1. ASSET-1 and ASSET-2 Study Design
Patients in both ASSET-1 and ASSET-2 were screened and randomized 1:1 to bosentan or
matching placebo based upon inclusion/exclusion criteria. After 4 weeks, bosentan dose was
increased from 62Æ5 mg b.i.d. to 125 mg b.i.d with a placebo dummy up-titration. At the
end of 16 weeks of study drug, patients had the option to enter into the ASSET-3 open-label
study.
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Fig 2. Patient Disposition
The number of patients from each study that completed each protocol phase.
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Fig 3. ASSET-1 Baseline Measurement Correlations
6-minute walk distance (6MWD) and haemodynamic parameter correlations (Spearman’s
rank correlation coefficients and P values).
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Fig 4. ASSET-2 Baseline Measurement Correlations
6-minute walk distance (6MWD) and haemodynamic parameter correlations (Spearman’s
rank correlation coefficients and P values).
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Fig 5. Changes in 6-Minute Walk Distances (6MWDs)
Changes from baseline to Week 16 are shown for all patients in ASSET-1 and ASSET-2.
Black bars indicate median 6MWD values.
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Fig 6. Changes in Pulmonary Vascular Resistance (PVR)
Changes from baseline to Week 16 are shown for all patients in ASSET-1 and ASSET-2.
Black bars indicate median PVR values.
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Table 1
Baseline Characteristics of ASSET-1 and ASSET-2 Enrolled Patients.
ASSET-1 ASSET-2
Characteristic N Median (IQR)1 N Median (IQR)1
Age, years 14 40 (34–53) 12 47.5 (38–54)
Female, n (%) 14 10 (71) 12 7 (58)
6MWD, m 14 353 (295–390) 12 370 (292–402)
Right heart catheterization
 mPAP, mm Hg 14 32 (30–39) 12 33 (29–40)
 mRAP, mm Hg 14 8 (5–10) 12 10 (8–14)
 PVR, dyn/sec/cm-5 14 262 (185–320) 11 144 (122–200)
 mPCWP, mm Hg 14 12 (10–15) 11 17 (15–21)
 CO, L/min 14 7.3 (6.6–8.1) 12 7.9 (6.8–9.1)
1
Interquartile range (25th-75th percentile), unless otherwise noted.
mPAP, mean pulmonary artery pressure; mRAP, mean right arterial pressure; PVR, pulmonary vascular resistance; mPCWP, mean capillary wedge
pressure; CO, cardiac output.
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Table 2
Correlations of 6MWD at Baseline with Baseline Hemodynamic Parameters.
ASSET-1 ASSET-2
N R (p) N R (p)
mPAP, mm Hg 14 0.11 (0.7) 12 0.01 (0.9)
mRAP, mm Hg 14 −0.48 (0.08) 12 0.17 (0.6)
PVR, dyn/sec/cm-5 14 −0.50 (0.07) 11 0.05 (0.9)
mPCWP, mm Hg 14 −0.14 (0.6) 11 −0.55 (0.08)
CO, L/min 14 0.69 (0.006) 12 0.55 (0.06)
mPAP, mean pulmonary artery pressure; mRAP, mean right arterial pressure; PVR, pulmonary vascular resistance; mPCWP, mean capillary wedge
pressure; CO, cardiac output
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Table 4
Pre-Treatment and Post-Treatment Results (Non-Parametric)
ASSET-1
Bosentan Placebo
Characteristic N Median Difference (IQR)1 N Median Difference (IQR)1
6MWD2 , m* 6 -9 (-18,-5) 7 38 (3, 52)
PVR, dyn/sec/cm-5 5 -90 (-111,-41) 4 -60 (-98, 8)
mPAP, mm Hg 5 -6 (-6, -5) 4 -4 (-8, 1)
mRAP, mm Hg 5 0 (-2, 0) 5 -2 (-3, 1)
mPCWP, mm Hg 5 -1 (-2, 1) 5 -2 (-3, 1)
CO, L/min 5 1.0 (-0.5, 4.0) 5 -0.3 (-0.3, 0.5)
ALT 6 -12(-25,-3) 7 -11(-20,-5)
Hb 5 0.10(-0.5,0.2) 7 -0.6(-1.2,0.5)
ASSET-2
Bosentan Placebo
Characteristic N Median Difference (IQR)1 N Median Difference (IQR)1
6MWD2, m 5 0 (-9, 0) 7 17 (-24, 80)
PVR, dyn/sec/cm-5 4 -77 (-116, 23) 7 -22 (-41, 40)
mPAP, mm Hg 5 -4 (-6, -4) 7 -5 (-8, 9)
mRAP, mm Hg 5 2 (1, 2) 7 -4 (-9, 2)
mPCWP, mm Hg 4 3 (1, 4) 7 -3 (-5, -1)
CO, L/min 5 1.0 (-0.8, 1.7) 7 -0.9 (-1.6, -0.2)
ALT 4 0 (-2,5.5) 6 -4(-6,-1)
Hb 4 -1.0(-1.6,-0.05) 5 0.70(-0.4,0.8)
*
1 of the 6 pts in the bosentan group of ASSET-1 died
No imputation rules were applied to missing hemodynamic data
1
Defined as week 16 visit median value minus baseline visit median value; IQR=Interquartile range (25th-75th percentile)
2
Last observation carried forward if 6MWD data missing, 0 m used in case of death 6MWD, 6-minute walk distance; mPAP, mean pulmonary
artery pressure; mRAP, mean right arterial pressure; PVR, pulmonary vascular resistance; mPCWP, mean capillary wedge pressure; CO, cardiac
output; ALT, alanine transaminase; Hb, haemoglobin.
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Table 5
Incidence of All Adverse Events (ASSET-1 and ASSET-2 Combined).
Parameter Bosentan (n=11) Placebo (n=15)
AEs
 Total patients with at least one AE, n (%) 9 (82) 13 (87)
  Total number of different AEs, n 48 72
   Total patients with an AE that led to premature discontinuation of study treatment, n (%) 2 (18) -
SAEs
 Deaths, n (%) 1 (9) -
  Total patients with at least one SAE, n (%) 5 (46) 6 (40)
  Total number of different SAEs, 11 15
AE, adverse event; SAE, serious adverse event.
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